Synthetic data, meaning text, images and tabular records produced by algorithms rather than collected from the real world, has moved from the research lab into everyday business use. It promises datasets that can be shared, tested and used to train AI without exposing real individuals. The law, however, does not accept that promise at face value. In 2026 the European Data Protection Board stated that synthetic data is not anonymous by default, the AI Act’s transparency duties for synthetic content began to apply, and Poland established its own AI supervisory authority. This article explains how synthetic data is generated and what legal conditions its generation and use must meet.
Online sales of semaglutide and other active substances in Poland – regulatory exposure for sellers, marketplaces, advertisers and logistics operators
Vials of semaglutide and other peptides are sold online in Poland as “research chemicals” and delivered to parcel lockers without a prescription. The label is meant to keep the product outside pharmaceutical law. It does not: under EU and Polish law the classification of a product follows its presentation and its effect, not the seller’s disclaimer. For businesses, the practical question is therefore not whether this trade is legal, but who in the chain – seller, marketplace, advertiser, influencer, payment or logistics provider – carries the criminal, administrative and civil risk, and how quickly Polish enforcement tools are catching up.
We are proud to announce that KG Legal Kiełtyka Gładkowski has been named a winner in the inaugural European Legal Awards 2026, hosted by EU Business News. The firm received the title Most Trusted Cross-Border Law Firm 2026 – Poland.
Poland’s Ministry of Health wants to place medicines with different active substances in a single reimbursement limit group where they work in a similar way, and to reward hospitals for choosing the cheapest therapy available. The change is meant to bring prices down and free up funds for innovative treatment, but clinicians warn that cost equivalence is not the same as clinical equivalence. We examine how the proposed baskets of equivalent therapeutic technologies could affect physicians’ autonomy, patients’ rights and competition in the pharmaceutical market, and what safeguards the legislation should contain. KG LEGAL KIELTYKA GLADKOWSKI supports international pharmaceutical, biotechnology and healthcare businesses operating in Poland. For legal assistance with pharmaceutical regulation, reimbursement and market access, contact our team at office@kg-legal.pl.
On 4 November 2026 the Polish statute of 18 September 2026 consenting to the ratification of the Treaty between the Republic of Poland and the United Kingdom on a Security and Defence Partnership, known as the Northolt Treaty, was signed. The remaining steps are ratification and the exchange of notifications between Warsaw and London; the Treaty enters into force 30 days after the later notification.